LAIR-1 agonism as a therapy for acute myeloid leukemia
Lovewell R, Hong J, Kundu S, Fielder C, Hu Q, Kim K, Ramsey H, Gorska A, Fuller L, Tian L, Kothari P, Paucarmayta A, Mason E, Meza I, Manzanarez Y, Bosiacki J, Maloveste K, Mitchell N, Barbu E, Morawski A, Maloveste S, Cusumano Z, Patel S, Savona M, Langermann S, Myint H, Flies D, Kim T. LAIR-1 agonism as a therapy for acute myeloid leukemia. Journal Of Clinical Investigation 2023, 133: e169519. PMID: 37966113, PMCID: PMC10650974, DOI: 10.1172/jci169519.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaLeukemic stem cellsMyeloid leukemiaPatient-derived xenograft modelsHealthy hematopoietic stem cellsStem cellsCare therapyLAIR-1LSC survivalAML blastsAgonist antibodyTherapeutic strategiesXenograft modelLeukemic cellsTherapeutic potentialHematopoietic stem cellsEffective eradicationTherapyLeukemiaCell deathAgonismSignaling programsCellsPresence of collagenAntibodies